Sac-TMT树立EGFR突变耐药NSCLC治疗新标杆：芦康沙妥珠(Sac-TMT)的III期OptiTROP-Lung04研究 (二线EGFR突变、TKI治疗进展的NSCLC，Sac-TMT单药对比铂类化疗)结果在ESMO大会公布：Sac- TMT治疗组相比对照组在PFS和OS上均取得统计学和临床的显著改善：中位PFS分别为8.3 vs.4.2个月， HR=0.49(95% CI：0.39-0.62，p<0.0001);中位OS为NRvs.17.4个月，HR=0.60(95% CI：0.44-0.82，双尾 p=0.001)，OSHR值显著优于同适应症其他各类疗法，该行认为一定程度上与该去化疗方案为后续治疗 提供更多选择、毒性累积较低有关。在所有预设关键亚组中也观察到了一致的OS和PFS获益，一线使用 三代EGFR治疗的患者中0.59的OSHR与总体人群一致。两组≥3级的TRAE相似(58% vs.53.8%)。该适应 症的上市申请已于10月获批上市。与同靶点竞品Dato-DXd相比，Sac-TMT的口腔黏膜炎、眼表毒性和 间质性肺炎等发生概率更低，血液学毒性发生率更高但临床管理更有经验。值得注意的是，在D ...

Sac-TMT树立EGFR突变耐药NSCLC治疗新标杆：芦康沙妥珠(Sac-TMT)的III期OptiTROP-Lung04研究 (二线EGFR突变、TKI治疗进展的NSCLC，Sac-TMT单药对比铂类化疗)结果在ESMO大会公布：Sac- TMT治疗组相比对照组在PFS和OS上均取得统计学和临床的显著改善：中位PFS分别为8.3vs.4.2个月， HR=0.49(95%CI：0.39-0.62，p<0.0001);中位OS为NRvs.17.4个月，HR=0.60(95%CI：0.44-0.82，双尾 p=0.001)，OSHR值显著优于同适应症其他各类疗法，该行认为一定程度上与该去化疗方案为后续治疗 提供更多选择、毒性累积较低有关。在所有预设关键亚组中也观察到了一致的OS和PFS获益，一线使用 三代EGFR治疗的患者中0.59的OSHR与总体人群一致。两组≥3级的TRAE相似(58%vs.53.8%)。该适应症 的上市申请已于10月获批上市。与同靶点竞品Dato-DXd相比，Sac-TMT的口腔黏膜炎、眼表毒性和间 质性肺炎等发生概率更低，血液学毒性发生率更高但临床管理更有经验。值得注意的是，在Dato- ...

智通财经APP获悉，交银国际发布研报称，协鑫科技(03800)在2025年第三季光伏材料业务分部利润9.6 亿元人民币(下同)(含出售联营公司鑫华半导体的税后利润6.4亿元)，扭亏为盈。在不得低于成本销售的 反内卷政策推动下，多晶硅价格7月下旬以来显著上涨，其中颗粒硅吨含税价格由最低3.4万元涨至目前 的5万元。同时，交银国际预计，开工率环比上升也显著摊薄单位折旧和费用，共同推动颗粒硅业务扭 亏。交银国际上调协鑫科技净利润预测，基于2026年市盈率16倍，目标价微调至1.54港元，维持"买 入"评级。 （原标题：交银国际：维持协鑫科技(03800)评级"买入" 多晶硅价格显著上涨推动扭亏） ...

交银国际发布研报称，协鑫科技(03800)在2025年第三季光伏材料业务分部利润9.6亿元人民币(下同)(含 出售联营公司鑫华半导体的税后利润6.4亿元)，扭亏为盈。在不得低于成本销售的反内卷政策推动下， 多晶硅价格7月下旬以来显著上涨，其中颗粒硅吨含税价格由最低3.4万元涨至目前的5万元。同时，交 银国际预计，开工率环比上升也显著摊薄单位折旧和费用，共同推动颗粒硅业务扭亏。交银国际上调协 鑫科技净利润预测，基于2026年市盈率16倍，目标价微调至1.54港元，维持"买入"评级。 ...

Core Viewpoint - The report from CMB International maintains a target price of HKD 183 for Kangfang Biopharma (09926) and expresses a long-term bullish outlook with a "Buy" recommendation, highlighting the company's overseas development progress and upcoming catalysts in the next 1-2 years [1] Group 1: Company Performance - Kangfang Biopharma's overseas development is gaining momentum, with significant catalysts expected in the near future [1] - The report notes that Summit Therapeutics has recently announced an expansion of the overseas research scale for Ivosidenib [1] Group 2: Clinical Data - Ivosidenib's second head-to-head Phase III study has yielded strong positive data, showing that the median progression-free survival (PFS) is significantly better than other PD-1 monotherapy drugs [1] - The absolute improvement in PFS for Ivosidenib compared to PD-1 exceeds the improvement seen with traditional chemotherapy [1] Group 3: Sales Expectations - The report maintains an expectation of peak sales in mainland China at RMB 7.1 billion [1]

Group 1 - The core viewpoint of the article indicates that the e-commerce sector is experiencing growth, with adjusted online retail sales in the physical e-commerce sector increasing by 7.5% year-on-year in Q3 [1] - The postal bureau anticipates a 12% year-on-year increase in express delivery volume in September, indicating stable growth [1] - The extended promotional period for the Double Eleven shopping festival is expected to drive growth in instant retail [1] Group 2 - The report forecasts that Alibaba's e-commerce GMV growth in September will align with the market average, while customer management revenue (CMR) growth will outpace GMV growth [1] - JD Group is expected to maintain steady retail growth in Q3, with improvements in average unit economics (UE) for its delivery services [1] - Kuaishou is projected to achieve a 15% year-on-year increase in e-commerce GMV in Q3 [1] Group 3 - Pinduoduo is expected to see marginal improvements in the second half of the year due to supportive policies and national subsidies [1] - The report provides price-to-earnings ratios for 2025: Alibaba at 19.7x, JD at 11.8x, Pinduoduo at 12.5x, and Kuaishou at 14.1x [1] - Alibaba's e-commerce market share is stabilizing, with a focus on restructuring its e-commerce framework through investments in instant retail and AI [1]

Core Viewpoint - The report from CMB International maintains a target price of HKD 183 for Kangfang Biotech (09926) and continues to recommend a "Buy" rating, expressing long-term confidence in the company due to its overseas development progress and upcoming catalysts in the next 1-2 years [1] Group 1 - The company is experiencing significant advancements in its overseas development, with a focus on expanding research efforts [1] - Summit Therapeutics has recently announced an expansion of the overseas research scale for Ivosidenib [1] - Ivosidenib's second head-to-head Phase III study has yielded strong positive data, showing a median progression-free survival (PFS) that significantly outperforms other PD-1 monotherapy drugs [1] Group 2 - The absolute improvement in PFS for Ivosidenib compared to PD-1 has exceeded the improvement seen with traditional chemotherapy [1] - The report maintains an expectation of peak sales in mainland China at RMB 7.1 billion [1]

Core Viewpoint - The report from交银国际 indicates that JD Group is expected to achieve a 13% year-on-year increase in total revenue for Q3, reaching 294.62 billion RMB, aligning with market expectations. The adjusted net profit is projected to be 4.2 billion RMB, with a profit margin of 1.4%, which is an improvement compared to 5.1% in the same period last year and 2.1% in Q2 [1] Revenue and Profit Forecast - Total revenue for JD Group in Q3 is anticipated to be 294.62 billion RMB, reflecting a 13% year-on-year growth [1] - The adjusted net profit is expected to be 4.2 billion RMB, corresponding to a profit margin of 1.4%, which is better than the previous year's 5.1% and Q2's 2.1% [1] Business Segment Performance - The retail business is projected to maintain steady growth, with a year-on-year increase of 10%, driven by double-digit growth in daily necessities, while the growth rate for electronics is expected to slow due to a high base from last year [1] - The order volume for the food delivery service in Q3 is expected to exceed that of Q2, with improvements in fulfillment efficiency and subsidy efficiency leading to a reduction in losses [1] - There is an expectation of increased cross-selling between the food delivery service and retail, with potential for more synergies during the e-commerce promotional period in Q4 [1]

Core Viewpoint - The report from CMB International indicates that JD Group (09618, JD.US) is expected to achieve a 13% year-on-year revenue growth in Q3, reaching 294.62 billion RMB, aligning with market expectations [1] Revenue and Profit Forecast - Total revenue for Q3 is projected at 294.62 billion RMB, reflecting a 13% increase compared to the previous year, consistent with institutional expectations [1] - Adjusted net profit is anticipated to be 4.2 billion RMB, corresponding to a profit margin of 1.4%, which is an improvement from 5.1% in the same period last year and 2.1% in Q2 [1] Business Segment Performance - The retail business is expected to maintain steady growth, with a year-on-year increase of 10%, driven by double-digit growth in daily necessities, while the growth rate for electronics is slowing due to a high base effect from last year [1] - The third quarter saw an increase in the order volume for food delivery compared to Q2, with improvements in fulfillment efficiency and subsidy efficiency leading to a reduction in losses [1] Future Outlook - The company is expected to further enhance cross-selling with retail during the fourth quarter's e-commerce promotional period, potentially leading to more synergistic effects [1]

Core Viewpoint - The report from交银国际 maintains a leading rating for the securities industry, highlighting high investment value and potential opportunities due to short-term market fluctuations [1] Group 1: Earnings and Growth - The brokerage firms are expected to see a 20% quarter-on-quarter increase in profits for Q3, with year-on-year growth anticipated to remain above 50% [1] - In the first half of the year, listed brokerages reported a 51.5% year-on-year profit increase, with Q1 and Q2 showing growth rates of 53% and 50% respectively [1] - The average daily trading volume of A-shares for the first three quarters was 1.62 trillion RMB, reflecting a year-on-year increase of 104.6%, with Q3 expected to show a 208.8% year-on-year growth due to a low base [1] Group 2: IPO and Fundraising - The A-share IPO fundraising amount for the first three quarters reached 77.3 billion RMB, a 62% year-on-year increase, significantly higher than the 15% growth in the first half [2] - Total equity fundraising amounted to 896.2 billion RMB, a 3.4 times increase year-on-year, with 376.2 billion RMB (an 84% increase) when excluding the directed issuance by state-owned banks [2] - The top three firms in A-share IPO underwriting amounts were 中金, 国泰海通, and 华泰, while 中金 led in Hong Kong stock underwriting [2] Group 3: Market Performance and Valuation - The A-share market saw significant gains in Q3, with the CSI 300 index rising by 17.9% in the first three quarters, while small-cap indices, particularly the ChiNext and Sci-Tech 50 indices, exceeded 50% growth [2] - The current price-to-book ratio for the A-share securities industry index is 1.45, which is below the historical median of 1.51, indicating that the sector is still undervalued despite strong expected earnings growth [2]